Comment on: A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 years results of the OPERA trial

Neoadjuvant treatment has revolutionized the management of localized rectal cancer, by reducing the incidence of local and distant recurrences, by downstaging the tumor and expanding the indication to surgery, and by allowing watch-and-wait strategy in selected patients with complete clinical and radiological responses.

Leave a Reply